{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:09:08Z","timestamp":1792156148339,"version":"4.4.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","award":["138587"],"award-info":[{"award-number":["138587"]}],"id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against omicron has been challenging to estimate in clinical studies or is not available for all vaccines or populations of interest. T cell function can be predictive of vaccine longevity and effectiveness against disease, likely in a more robust way than antibody neutralization. In this mini review, we summarize the evidence on T cell immunity against omicron including effects of boosters, homologous versus heterologous regimens, hybrid immunity, memory responses and vaccine product. Overall, T cell reactivity in post-vaccine specimens is largely preserved against omicron, indicating that vaccines utilizing the parental antigen continue to be protective against disease caused by the omicron variant.<\/jats:p>","DOI":"10.3389\/fimmu.2022.944713","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T06:21:43Z","timestamp":1658816503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Post-vaccination T cell immunity to omicron"],"prefix":"10.3389","volume":"13","author":[{"given":"Henning","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Cobos Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Sitaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naor","family":"Bar-Zeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"\u010ci\u010din-\u0160ain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Higdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Deloria-Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"B1","unstructured":"Coronavirus disease (COVID-19): Vaccines"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103227","article-title":"Tracking the emergence of SARS-CoV-2 alpha variant in the united kingdom","volume":"385","author":"Walker","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","unstructured":"Tracking SARS-CoV-2 variants"},{"key":"B4","first-page":"ofac138","article-title":"A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease","volume-title":"Open Forum Infectious Diseases","author":"Higdon","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"ciac125","DOI":"10.1093\/cid\/ciac125","article-title":"Household transmission of SARS-CoV-2 alpha variant \u2013 United States, 2021","author":"Donnelly","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04342-0","article-title":"Enhanced fitness of SARS-CoV-2 variant of concern alpha but not beta","volume":"602","author":"Ulrich","year":"2022","journal-title":"Nature"},{"key":"B7","article-title":"Results of studies evaluating the impact of SARSCoV-2 variants of concern on COVID-19 vaccines: An ongoing systematic review","author":"Jacobsen","year":"2021","journal-title":"View-hub"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00121-z","article-title":"Fast-spreading COVID variant can elude immune responses","volume":"589","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101190","article-title":"Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study","volume":"42","author":"Singer","year":"2021","journal-title":"eClinicalMedicine"},{"key":"B10","volume-title":"COVID-19 weekly epidemiological update","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.21.21265216","article-title":"Generation time of the alpha and delta SARS-CoV-2 variants: An epidemiological analysis","author":"Hart","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"103467","DOI":"10.1016\/j.isci.2021.103467","article-title":"SARS CoV-2 delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera","volume":"24","author":"Kuzmina","year":"2021","journal-title":"iScience"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010022","article-title":"Reduced neutralisation of the delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination","volume":"17","author":"Davis","year":"2021","journal-title":"PLoS Pathog"},{"key":"B14","unstructured":"Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern2021"},{"key":"B15","volume-title":"Weekly epidemiological update on COVID-19","year":"2022"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 omicron variant: Recent progress and future perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"B17","volume-title":"Weekly epidemiological update on COVID-19","year":"2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01432-4","article-title":"A correlate of protection for SARS-CoV-2 vaccines is urgently needed","volume":"27","author":"Krammer","year":"2021","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.21.21267898","article-title":"Diminished neutralization responses towards SARS-CoV-2 omicron VoC after mRNA or vector-based COVID-19 vaccinations","author":"Jacobsen","year":"2022"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.xcrm.2022.100529","article-title":"mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant","volume":"3","author":"Edara","year":"2022","journal-title":"Cell Rep Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.27.21264163","article-title":"Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines","author":"van Gils","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21268048","article-title":"Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles","author":"Syed","year":"2022"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04466-x","article-title":"Memory b cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants","volume":"603","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101505","DOI":"10.1016\/j.smim.2021.101505","article-title":"T Cell immunity to SARS-CoV-2","volume":"55","author":"Niessl","year":"2021","journal-title":"Semin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-Specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.23.465542","article-title":"Protection from SARS-CoV-2 delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway","author":"Gagne","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4509","article-title":"Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2","volume":"6","author":"Israelow","year":"2021","journal-title":"Sci Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Moderbacher","year":"2020","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"100354","DOI":"10.1016\/j.xcrm.2021.100354","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory b and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04280-x","article-title":"Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection","volume":"602","author":"Adamo","year":"2022","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2108829","article-title":"Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-Specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.06.471446","article-title":"Minimal cross-over between mutations associated with omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals","author":"Redd","year":"2021","journal-title":"bioRxiv"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.12.472315","article-title":"SARS-CoV-2 T cell responses are expected to remain robust against omicron","author":"Ahmed","year":"2021"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.18.21265113","article-title":"Immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant in provincetown, Massachusetts","author":"Collier","year":"2021"},{"key":"B51","doi-asserted-by":"publisher","first-page":"eabj1750","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.chom.2021.10.003","article-title":"Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner","volume":"29","author":"Keeton","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/eji.202170126","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (Third edition)","volume":"51","author":"Cossarizza","year":"2021","journal-title":"Eur J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04460-3","article-title":"T Cell responses to SARS-CoV-2 spike cross-recognize omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-Specific T cells cross-recognize the omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00838-5","article-title":"T Cell epitopes in SARS-CoV-2 proteins are substantially conserved in the omicron variant","volume":"19","author":"Choi","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.02.21267198","article-title":"Homologous and heterologous vaccine boost strategies for humoral and cellular immunologic coverage of the SARS-CoV-2 omicron variant","author":"Tan","year":"2021"},{"key":"B60","doi-asserted-by":"publisher","first-page":"eabo2202","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 omicron\u2013reactive T and b cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"","journal-title":"Sci Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2022.01.029","article-title":"T Cell reactivity to the SARS-CoV-2 omicron variant is preserved in most but not all individuals","volume":"185","author":"Naranbhai","year":"2022","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.30.474453","article-title":"Preserved T cell reactivity to the SARS-CoV-2 omicron variant indicates continued protection in vaccinated individuals","author":"De Marco","year":"2021"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.801431","article-title":"SARS-CoV-2 spike-specific CD4+ T cell response is conserved against variants of concern, including omicron","volume":"13","author":"Mazzoni","year":"2022","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.16.21266350","article-title":"A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize delta and omicron variants of concern","author":"Schultz","year":"2022"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.15.22270973","article-title":"An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile","author":"Soto","year":"2022"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21268128","article-title":"Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-Treated multiple sclerosis patients","author":"Madelon","year":"2021"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2118312119","article-title":"Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants","volume":"119","author":"Kingstad-Bakke","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-Cell-Inducing vaccines \u2013 what\u2019s the future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01534-18","article-title":"Why are CD8 T cell epitopes of human influenza a virus conserved","volume":"93","author":"Li","year":"2019","journal-title":"J Virol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant in south Africa","volume":"386","author":"Collie","year":"2022","journal-title":"New Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.28.21268436","article-title":"Vaccine effectiveness against hospital admission in south African health care workers who received a homologous booster of Ad26.COV2 during an omicron COVID19 wave: Preliminary results of the sisonke 2 study","author":"Gray","year":"2021"},{"key":"B73","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","article-title":"Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization","volume":"12","author":"Lapuente","year":"2021","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines \u2014 fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.944713\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T11:32:33Z","timestamp":1659612753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.944713\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2022.944713"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.944713","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"944713"}}